The World Health Organisation (WHO) has approved an antiviral drug, molnupiravir, for the treatment of omicron variant of the deadly coronavirus.
WHO gave the approval in the ninth update on COVID-19 therapeutics made available on its website on Thursday.
READ ALSO: COVID-19: Nigerian Gov’t to vaccinate Nigerians in Churches on Sundays
This will be the first oral antiviral drug included in the treatment for COVID-19 after the development of vaccines in mid 2020.
The body urged stakeholders and health workers to ensure active monitoring for drug safety, along with other strategies to mitigate potential harms as the approval was based on conditional recommendation, according to PUNCH.
Aside from its new approval, the global health body also recommended that casirivimab-imdevimab should not be used for patients infected with the Omicron variant.
“Because of these concerns and data gaps, molnupiravir should be provided only to non-severe COVID-19 patients with the highest risk of hospitalization. These are typically people who have not received a COVID-19 vaccination, older people, people with immunodeficiencies, and people living with chronic diseases,” the health body stated.
“Children, and pregnant and breastfeeding women should not be given the drug. People who take molnupiravir should have a contraceptive plan, and health systems should ensure access to pregnancy testing and contraceptives at the point of care.
“Under the care of a health care provider, molnupiravir, an oral tablet, is given as four tablets (total 800 mg) twice daily for five days; within 5 days of symptom onset. Used as early as possible after infection, it can help prevent hospitalization.
“Today’s recommendation is based on new data from six randomized controlled trials involving 4796 patients. This is the largest dataset on this drug so far.”
Follow the Neptune Prime channel on WhatsApp: https://whatsapp.com/channel/0029Va74ZvU2v1IqKByXoX3d
Do you have breaking news, interview request, opinion, suggestion, or want your event covered? Email us at neptuneprime2233@gmail.com
 has approved an antiviral drug, molnupiravir, for the treatment of omicron variant of the deadly coronavirus. ){kind=link}